First, RhoAG17V mutations of gastric carcinomas [27] may confer structural resistance to canonical inhibitors like SC by stabilizing GTP-bound RhoA, necessitating mutant-allele-specific therapeutic development. Here, RHOA is linked to gastric carcinoma.